SOHM, Inc.

Your product shouldn’t outgrow your manufacturer.🧪 From prototype batches to full commercial manufacturing, SOHM is built to grow with you. Start with SOHM. $SHMN

Happy Diwali! 🪔 To everyone who is part of the SOHM community, our team, customers, partners, suppliers, and shareholders, we wish you a Diwali filled with family, laughter, and sweet moments. May the year ahead bring you health, happiness, and prosperity. From all of us at SOHM, have a wonderful Diwali.

Exciting momentum continues at SOHM! We have received many inquiries from shareholders and customers about our gummy inventory across Amazon US/UK, Walmart Marketplace, our e-commerce store, and other distribution channels. Despite recent tariff, geopolitical, and supply-chain challenges, production is underway and our gummy line is being redesigned and refreshed. We currently expect inventory replenishment within 30–45 days, with new gummy products also planned for next month. Meanwhile, we are moving forward with: - SOHM Pain Away - Fohm by SOHM - Nail Renovar & Nail Renovar Plus+ - New gummy products and refresh - Ongoing manufacturing operations - ABBIE biotech experiments and deeper validation🧬 To our shareholders, customers, partners, distributors, and supporters: thank you for your continued confidence, patience, and enthusiasm. We are excited about what lies ahead! $SHMN

Hundreds of CDMOs. Here's why brands choose SOHM. 🧪 Collaborative. Flexible. Technical. Quality driven. End to end. The right CDMO changes everything. $SHMN

Rx. OTC. Cosmetics. One quality system covers all three. 💊 SOHM has the framework. $SHMN

Modern equipment. Documented systems. Zero guesswork. SOHM’s facility is built for consistency at every scale. $SHMN

We wish everyone a Happy Labor Day! Today is a moment to pause and appreciate the effort, dedication, and belief that goes into building something meaningful and impactful. We are grateful for every contribution, big and small, that keeps this journey moving forward.

Not every manufacturer is a partner. At SOHM, we don't just manufacture, we develop, optimize, validate, and scale alongside you. One partner, full lifecycle. $SHMN

SOHM, Inc. Q2 2026 Update We are pleased to share that our Q2 2026 financial results have been published on OTC Markets and are now available for review. While our Q2 performance did not meet management's expectations, we believe the results reflect a temporary phase driven primarily by external market conditions beyond the Company's control. Global geopolitical uncertainties, supply chain disruptions, and tariff-related pressures in the USA significantly impacted the availability and pricing of both raw materials and finished products across multiple sectors. Despite these challenges, SOHM remained committed to maintaining product quality, customer service, and operational discipline. Looking ahead, management remains optimistic and expects Q3 revenue performance to be more closely aligned with prior-year levels as market conditions stabilize and new initiatives gain momentum. Growth Initiatives Underway Our Pharmaceutical, Nutraceutical, and Biotechnology divisions continue to advance several strategic growth programs, including: ✅ Expansion into India and Middle Eastern markets ✅ Increased focus on e-commerce, quick commerce, and digital distribution channels ✅ New product launches across pharmaceutical, nutraceutical, and wellness categories ✅ Strengthening international distribution partnerships ✅ More revenue streams through the CDMO activities ABBIE Biotechnology Progress Our biotechnology division continues to make significant progress with the ABBIE™ gene-editing, gene-integration, and delivery platform. The Company is currently engaged in discussions with multiple organizations regarding: • Licensing opportunities for ABBIE technology applications in CAR-T and Cell Therapy development • Cell-line engineering solutions • Advanced drug delivery technologies • Potential co-development and strategic partnership opportunities A Long-Term Scientific Approach Biotechnology innovation is inherently data-driven and requires rigorous scientific validation, optimization, and regulatory review. Our team continues to advance ABBIE through ongoing experimentation, repeated validation studies, and customized development pathways designed to address diverse therapeutic applications. While scientific progress often requires patience and precision, we remain encouraged by the results achieved to date and the growing interest from potential collaborators. Looking Forward Despite near-term market headwinds, SOHM remains focused on executing its long-term strategy, expanding global market access, advancing innovation, and creating sustainable value for shareholders. We thank our shareholders, customers, partners, and employees for their continued support and confidence as we build the next phase of SOHM's growth. The future remains bright, and we are excited about the opportunities ahead. $SHMN #SOHM #Biotech #Pharmaceuticals #Nutraceuticals #ABBIE #GeneEditing #CellTherapy #HealthcareInnovation #OTCMarkets #GrowthStrategy #LifeSciences #ShareholderUpdate

New Oxford research shows how T cells decide to attack or ignore cancer cells. It reinforces why platforms like ABBIE, built for complex genetic programming, matter for the next generation of immunotherapy. $SHMN